Influence of XOI, Febuxostat, on Vascular Function in Patients with Hyperuricemia and Cardiovascular Risk Factors

Influence of XOI, Febuxostat, on Vascular Function in Patients with Hyperuricemia and Cardiovascular Risk Factors - Jichi Medical Univertisy XOI study (J-XOI study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019530

Enrollment

100

Registered

2015-10-28

Start date

2015-10-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

(1) Treated or untreated hyperuricemia and (2) Hypertension, ischemic heart disease, diabetes, dyslipidemai, chronic kidney disease (CKD), history of cerebrovascular diease, aortic dissection, or metabolic syndrome

Interventions

Febuxostat Febuxostat will be administered from 10mg, and then increaed to 20 and 40mg, after 4wks and 8wks, respectively. Serum uric acid is measured before increasing febuxostat, and if uric a

6.0mg/dl, febuxostat will not be increased. Allopurinol Allopurinol will be started from 100mg/day and will be incraed to 200mg after 4 wks. Follow up period is 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Treated or untreated patients with Hyperuricemia (2) Hypertension, ischemic heart disease, diabetes, dyslipidemai, chronic kidney disease (CKD), history of cerebrovascular diease, aortic dissection, or metabolic syndrome (3) Age 20 years or more (4) Patients who are treated with uric acid lowering agens (5) Patinets from which informed consent is obtained and who are able to be followed for 6 months

Exclusion criteria

Exclusion criteria: (1) Age < 20years (2)Patients having gout attack at the time of eligibility judgment (3)Patients with renal failure, or dialysis (4)Patients with hepatic impairment (5)Patinets having malignancy, chemotherapy, psoriasis vulgaris, polycythemia, hemolytic anemia, myopathy, PRPP synthetaze activation, Lesch-Nyhan syndrome (HPRT deficiency), Diabetes insipidus, or other severe diseases (6)Patients with hypersensitivity to febuxostat (7)Treated patients with mercaptopurine or azathioprine, aciclovir, and didanosine (8)Pregnant female, lactation femal, hoping gestation (9)Patients whom study physicians consider as not eligible.

Design outcomes

Primary

Measure	Time frame
Changes of flow-mediated dilatation (FMD), pulse wave velocity (PWV), central pressure, carotid intima-media thickness (IMT) at 6 months after the intervention.	—

Countries

Japan

Contacts

Public ContactKazuomi Kario

Jichi Medical University School of Medicine Division of Cardiovascular Medicine, Department of Medicine

kkario@jichi.ac.jp0285-58-7344

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026